Genmab A/S (NASDAQ:GMAB) Stock Jumps 7.4% – Should You Buy?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) shares traded up 7.4% on Friday. The stock traded as high as $40.29 and last traded at $42.9540. 1,785,023 shares traded hands during mid-day trading, a decline of 19% from the average session volume of 2,207,187 shares. The stock had previously closed at $40.00.

Analysts Set New Price Targets

Several equities analysts recently weighed in on GMAB shares. Morgan Stanley set a $42.00 price target on shares of Genmab A/S in a research report on Tuesday. Truist Financial raised their price objective on Genmab A/S from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. TD Cowen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating and increased their target price for the company from $32.00 to $43.00 in a report on Wednesday, July 22nd. Guggenheim boosted their price target on shares of Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Finally, New Street Research set a $43.00 price objective on shares of Genmab A/S in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $43.39.

Genmab A/S Price Performance

The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. The business has a 50-day moving average price of $35.01 and a 200 day moving average price of $30.12. The stock has a market cap of $26.67 billion, a PE ratio of 33.62, a PEG ratio of 1.80 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. As a group, research analysts forecast that Genmab A/S Sponsored ADR will post 1.23 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of GMAB. WINTON GROUP Ltd grew its position in shares of Genmab A/S by 158.9% during the 2nd quarter. WINTON GROUP Ltd now owns 40,900 shares of the company’s stock valued at $1,124,000 after purchasing an additional 25,100 shares in the last quarter. SummitTX Capital L.P. purchased a new stake in shares of Genmab A/S in the first quarter worth $2,263,000. Diversify Wealth Management LLC purchased a new stake in shares of Genmab A/S in the first quarter worth $1,216,000. Legacy Wealth Asset Management LLC boosted its stake in Genmab A/S by 164.1% during the second quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock valued at $2,806,000 after buying an additional 63,484 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Genmab A/S by 26.4% during the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after buying an additional 921,700 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.